Abstract
Autologous activated macrophage (AAM) therapy is an adoptive cellular therapy based on ex vivo differentiation and activation of autologous peripheral blood monocytes. This study was undertaken to evaluate the tolerance, efficiency and biological effects of AAMs in chemoresistant progressive colorectal cancers. From January 1993 to May 1995, 15 patients were treated. Mononuclear cells were collected six times by weekly apheresis, cultured for 7 days, and activated with interferon-gamma. AAMs were then separated by elutriation and re-infused intravenously, with a mean total of 7.95 x 10(9) macrophages per patient. Clinical tolerance was good: toxicity consisted only of a World Health Organisation grade 2 fever after 28% of the infusions. Responses were not seen in the 14 evaluable patients, as expected with very bulky tumours: in 11, the tumours continued to progress, but disease was stabilised in 3 patients who experienced progression-free survival for 14, 12 and 12 weeks, respectively.
References
Jul 1, 1992·Immunology Today·A MantovaniL Ruco
Apr 1, 1992·Journal of Immunotherapy·M LopezO Mortel
Jan 1, 1992·Research in Immunology·R J StreckJ L Pauly
Jan 1, 1992·Research in Immunology·S HarwixG Schwamberger
Jan 1, 1991·Cancer Immunology, Immunotherapy : CII·A FaradjiP Poindron
Feb 15, 1992·Cancer·F LéviA Descorps-Declère
Aug 5, 1986·Biochimica Et Biophysica Acta·A MantovaniB Bottazzi
Nov 15, 1988·Biochimica Et Biophysica Acta·I J Fidler, A J Schroit
Nov 1, 1988·European Journal of Cancer & Clinical Oncology·S DumontJ Bartholeyns
Sep 1, 1988·European Journal of Cancer & Clinical Oncology·A De GramontC Louvet
Dec 22, 1988·The New England Journal of Medicine·S A RosenbergC A Seipp
Jul 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·J L UrbanH Schreiber
Apr 9, 1987·The New England Journal of Medicine·S A RosenbergJ T Rubin
Feb 26, 1993·Journal of Immunological Methods·M LopezJ Bartholeyns
Apr 1, 1961·Journal of Chronic Diseases·E A GEHAN
Citations
Feb 22, 2002·The Journal of Pathology·L BingleClaire E Lewis
Nov 15, 2000·La Revue de médecine interne·J BartholeynsJ L Romet-Lemonne
Dec 16, 1998·Research in Immunology·T LesimpleL Toujas
Nov 5, 2002·Critical Reviews in Oncology/hematology·A H KlimpT Daemen
Apr 4, 2003·Critical Reviews in Oncology/hematology·Piero DalerbaGiorgio Parmiani
Oct 26, 1999·Transfusion·P NguyênG Potron
Apr 2, 2003·Cancer Biotherapy & Radiopharmaceuticals·Yukio IwashitaSeigo Kitano
Feb 24, 2007·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Samuel BaronKathryn Zoon
Oct 23, 2002·Clinical and Experimental Immunology·A L MillardJ Bernard
Jan 6, 2015·Journal of Cellular Physiology·Silvia CarluccioMarco Bregni
Jan 7, 2016·Nanomedicine : Nanotechnology, Biology, and Medicine·Jinglong TangYing Liu
Jan 20, 2000·Current Medical Research and Opinion·S Kochman, J Bernard
Feb 8, 2014·PloS One·Cheryl A LondonSharon Shacham
Jul 17, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Simon LeeFrancis C Szoka
Sep 8, 2004·Veterinary Immunology and Immunopathology·Camila Miranda de CarvalhoDominique Rigal
Jun 18, 2002·Chest·Isabelle MonnetManuel Lopez
Jul 29, 2010·Pharmaceuticals·Joseph BekiszKathryn C Zoon
Nov 20, 2016·Physiological Reports·Rajamouli PasulaWilliam J Martin
Nov 23, 2017·Biology Open·Fidel-Nicolás LoloSergio Casas-Tintó
Sep 20, 2000·Leukemia·L ChaperotJ Plumas
May 9, 2000·Gene Therapy·H LeiX Cao
Jan 7, 2006·Gene Therapy·A BiglariD E Gilham
Jun 12, 1998·Journal of Surgical Oncology·M L Salgaller, P A Lodge
Mar 19, 1999·Annals of Surgical Oncology·M A Morse, H K Lyerly
Jan 23, 2018·Frontiers in Immunology·Elina SimanovichMichal A Rahat
Jul 20, 2007·Cancer Research·Geun Taek LeeIsaac Yi Kim
Jan 23, 2021·DNA and Cell Biology·Ahmed SalahYuehong Wu